Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.

Abstract

To critically appraise published network meta-analyses (NMAs) evaluating the efficacy or safety of the new oral anticogulants (NOACs) dabigatran, rivaroxaban, and apixaban for the prevention of stroke in patients with nonvalvular atrial fibrillation (AF).

Journal

Journal ID (iso-abbrev): Value Health

Title: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

ISSN (Electronic): 1524-4733

ISSN (Print): 1098-3015

Publication date (Electronic): Mar 2015

Volume: 18

Issue: 2

Affiliations

[1 ] Mapi, Health Economics and Outcomes Research, Toronto, ON, Canada. Electronic address: [e-mail].

[2 ] Corporate Division Medicine, TA Cardiology, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; Center of Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany.

[3 ] Boehringer Ingelheim, Paris, France.

[4 ] Medical Data Services, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.

[5 ] Tufts University School of Medicine, Boston, MA, USA.

Article

Publisher Item ID: S1098-3015(14)04738-X

DOI: 10.1016/j.jval.2014.10.012

PubMed ID: 25773559

Copyright statement: Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.